TRCCC 2018: Single-Cell TILs Polyfunctionality Associates with Clinical Outcome of Anti-PD-1 Therapy

IsoPlexis presented “Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy” at the Translational Research Cancer Centers Consortium (TRCCC) 2018 in Seven Springs, PA. The study found an association between CD8+ TILs polyfunctionality and the clinical outcome of melanoma patients on Anti-PD-1 therapy. TRCCC works to expedite the progress in immunotherapy and other biologic therapies. TRCCC brings together leaders in this field to advance science, collaboration and clinical trials to help individuals diagnosed with cancer.

Share This Article
Follow the Data.
Your Data is Secure

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.